Sage Therapeutics, Inc. (SAGE) Position Boosted by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 41.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,682 shares of the biopharmaceutical company’s stock after acquiring an additional 2,525 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Sage Therapeutics were worth $691,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares during the period. Turner Investments LLC purchased a new position in Sage Therapeutics during the 2nd quarter valued at $159,000. Dubuque Bank & Trust Co. purchased a new position in Sage Therapeutics during the 2nd quarter valued at $167,000. Canada Pension Plan Investment Board purchased a new position in Sage Therapeutics during the 2nd quarter valued at $175,000. Finally, Teacher Retirement System of Texas purchased a new position in Sage Therapeutics during the 2nd quarter valued at $202,000.
A number of equities analysts recently issued reports on the company. Canaccord Genuity dropped their price objective on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday, September 12th. J P Morgan Chase & Co decreased their target price on Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a research report on Tuesday, September 12th. Cowen and Company decreased their target price on Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, September 12th. Stifel Nicolaus started coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They set a “buy” rating and a $104.00 target price for the company. Finally, BidaskClub lowered Sage Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $86.50.
ILLEGAL ACTIVITY NOTICE: “Sage Therapeutics, Inc. (SAGE) Position Boosted by Raymond James Financial Services Advisors Inc.” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://theolympiareport.com/2017/10/31/sage-therapeutics-inc-sage-position-boosted-by-raymond-james-financial-services-advisors-inc.html.
Sage Therapeutics, Inc. (SAGE) opened at 63.36 on Tuesday. The company’s 50-day moving average price is $64.26 and its 200 day moving average price is $73.78. Sage Therapeutics, Inc. has a 52 week low of $38.30 and a 52 week high of $90.80. The stock’s market capitalization is $2.37 billion.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same quarter last year, the business posted ($1.08) earnings per share. Equities research analysts expect that Sage Therapeutics, Inc. will post ($7.40) EPS for the current fiscal year.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.